12,372 trials
Spinocerebellar Ataxias · Spinocerebellar Ataxia Genotype Type 1 · Spinocerebellar Ataxia Genotype Type 2
Primary: Change From Baseline in Total Score on the Scale for the Assessment and Rating of Ataxia (SARA) at Randomization Phase Week 8 — -0.810; -1.059 score on a scale — p=0.519
Unrecognized Condition
Primary: Boston Bowel Preparation Scale — 169; 163 Number of successful cleansing
Dermatitis, Atopic
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 — 11.4; 32.8; 29.5 Percentage of Participants — p== 0.0004
Epilepsy · Partial-onset Seizures
Primary: Number of Participants With at Least One Adverse Event Reported Spontaneously by the Subject or Observed by the Investigator From Baseline Until the End of Study Visit…
Type 2 Diabetes
Primary: Change in HbA1c From Baseline to 24 Weeks — -0.6; -0.66 percent
Inflammation · Platelet Dysfunction
Primary: Change in Platelet Count — -221; -242 Count of platelets — p=0.55
Lymphoma
Primary: Percentage of Participants With Administration-Associated Reactions (AAR) — 4.2; 8.1; 6.3; 0 Percentage of Participants
Hemophilia A
Primary: Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay — 31.11 percentage of participants
Age-Related Macular Degeneration · Macular Degeneration · Wet Macular Degeneration
Primary: Frequency of Clinically Relevant Treatment Emergent ECG Changes After Intravitreal Injection of Brolucizumab 6 mg in Patients With nAMD — 0 Number of events
Binge Eating Disorder
Primary: Frequency and Severity of Suicidal Ideation Using the Columbia-suicide Severity Rating Scale (C-SSRS) — 515; 7; 3; 1 Participants
Chlamydia Trachomatis Infection
Primary: Urogenital CT Infection — 14; 28 Participants — p=0.0256
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) — 0.294; 0.284; 0.308; 0.240 Liter
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -17.4; -20.1 units on a scale — p=<.001
Atopic Dermatitis
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement — 14.7; 23.9; 30.6 percentage of participants — p=0.082
Atrophy
Primary: Percentage of Subjects Identified as Responders — 36.8; 32.0; 0.8 percentage of responders